Next-Generation Cytotoxic Therapeutics That Stimulate the Immune System by Selectively Killing Cancer Cells
Onchilles Pharma is developing first-in-class therapeutic elastases that harness the ELANE pathway. The result is broad, cancer-selective tumor killing that spares immune cells and activates systemic anti-tumor immunity.
Preclinical data. N17350 is investigational.
The ELANE Pathway Unlocks a New Approach to Selective Cancer Killing
At the core of this approach is the ELANE pathway, a unique cancer-selective killing mechanism that targets altered histone H1 biology, an essential vulnerability shared by all cancer cells. By targeting the ELANE pathway and inducing immunogenic cancer cell death, N17350 (NEU-001) and NEU-002 are designed to rapidly eliminate tumors while mobilizing an adaptive immune response, offering the potential for sustained anti-tumor immunity.
Targeting the ELANE pathway enables the selective eradication of cancer cells regardless of their genetic makeup, anatomical origin, or immune status. Onchilles has rigorously validated this approach across 12 distinct cancer types, over 30 genetically diverse cell lines, and more than 19 animal models. This body of evidence supported the rapid clinical advancement of ELANE pathway-targeting therapies, now in first-in-human testing, as a fundamentally new class of cancer-selective cytotoxic treatments.
About Onchilles Pharma
Onchilles Pharma is a clinical-stage biotechnology company pioneering first-in-class cytotoxic therapies designed to selectively kill cancer cells while preserving and activating immune function. By harnessing the ELANE pathway, these next-generation therapeutics are designed to deliver potent and selective tumor cell destruction, overcoming the limitations of traditional chemotherapy, targeted therapies, and immunotherapy.
The company's lead program, N17350 (NEU-001), a tumor-directed cytotoxic agent, is in the clinic. OP-NEU-101, a Phase 1/2 open-label, dose-finding and expansion study of intratumoral N17350 in advanced solid tumors, is enrolling at sites in the US and Australia (NCT07339176). Its intravenous counterpart, NEU-002, continues through preclinical development. With an extensive translational dataset validating its approach, Onchilles is leading the way in developing safer, more effective cytotoxic therapies that kill tumors specifically, spare healthy tissue, and activate the immune system for long-term anti-cancer immunity.
Onchilles Pharma is eliminating the trade-off between tumor-killing efficacy and immune preservation with a novel class of cytotoxic therapeutics that selectively destroy cancer cells to activate systemic anti-tumor immunity.
A New Class of Selective Cytotoxic Therapeutics with Unique Immune System Activation
Onchilles Pharma has established a leadership position in targeting the ELANE pathway, translating this approach into two proprietary molecules, N17350 (NEU-001) for intratumoral delivery and NEU-002 for systemic delivery. Both have the potential to transform cancer treatment by delivering broad tumor-killing capabilities while preserving and activating immune function. No current cytotoxic agent or immunotherapy meets this need.
Latest News
Keep up to date with all the latest news from Onchilles Pharma.
- Clinical
Onchilles Pharma to Present OP-NEU-101 Trial in Progress at ESMO Congress 2026
Onchilles Pharma, a clinical-stage biotechnology company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced that a Trial in Progress abstract for…
- Clinical
Onchilles Pharma Doses First Patient in Phase 1/2 Clinical Trial of N17350 for Advanced Solid Tumors
N17350 is a tumor-directed therapeutic elastase designed to selectively kill cancer cells, while preserving immune cells, and to stimulate anti-tumor
Questions About N17350 or the ELANE Pathway?
We welcome conversations with clinical investigators, scientific collaborators, and industry partners.